

# Contents

---

## Section 1: R&D Spending

### *Pharmaceuticals*

Trends in Worldwide Pharma and Biotech R&D Expenditures, 2002-2016P (EvaluatePharma) . . . . .	1
Global R&D Spending by World's Top 500 Pharma and Biotech Companies 2002-2016P (EvaluatePharma) . . . . .	1
R&D Spending by Research-Based Pharmaceutical Companies (PhRMA), 1980-2009 . . . . .	2
R&D Investments by Research-Based Pharmaceutical Companies (PhRMA), 1975-2009 . . . . .	2
Industry-wide and Government R&D Spending, 1980-2009 . . . . .	3
Biopharmaceutical Industry Investment in Research and Development, 1980-2009 . . . . .	3
Biopharmaceutical R&D Expenditure and NIH Budget: 1995-2009 . . . . .	3
AZ's Brennan on R&D Spending Trends Going Forward . . . . .	3
Analysis of Top 20 Companies by 2009 Pharma R&D Spend (EvaluatePharma) . . . . .	4
Top 20 Companies by Pharma R&D Spend in 2009 (EvaluatePharma) . . . . .	4
Top 20 Companies by Projected Pharma R&D Spend in 2016 . . . . .	4
Top 20 Companies by Pharma R&D Spend as a % of Pharmaceutical Revenues 2008 vs. 2009 (EvaluatePharma) . . . . .	4
Top 20 Companies by Count of Late Stage Projects (Phase II to Filed) and PDUFA Dates . . . . .	5
Top 20: Average R&D Spend per Late-Stage Project in 2009 (EvaluatePharma) . . . . .	5
Total PhRMA R&D as a Percent of Sales, 1994-2009 . . . . .	6
Domestic U.S. R&D and R&D Abroad, 1995-2009 . . . . .	6
Domestic U.S. Sales and Sales Abroad, 1995-2009 . . . . .	6
Growth in Domestic U.S. R&D and R&D Abroad, 1970-2009 . . . . .	7
Various Measures of New Drug/Biologic R&D Productivity, 1993-2009 . . . . .	8
Industry R&D Spending per NDA Submission in the U.S., 1993-2009 . . . . .	8
Industry R&D Spending per NDA Approval in U.S, 1996-2009 . . . . .	8
Industry R&D Spending per NME Submission to FDA, 1995-2009 . . . . .	8
Industry R&D Spending per NME Approved in the U.S., 1995-2009 . . . . .	8
Global R&D Spending per Global New Active Substance (NAS) Launch, 1995-2009 . . . . .	8
Comparative R&D Spending, Sales, and Product Launch Trends Worldwide: A 2010 Analysis . . . . .	9
Breakdown of World Pharma Market—2009 Sales . . . . .	9
Markets of First Launch for 25 NASs Introduced in 2009 . . . . .	9
Pharmaceutical R&D Expenditure Annual Growth Rate, US vs. Europe, 1994-2009 . . . . .	9
Pharmaceutical R&D Expenditure in Europe, the United States, and Japan, 1990-2009 . . . . .	9
U.S., European, Canadian, and Asia/Pacific Biotech: Global Activity Measures, 2009 . . . . .	10
U.S. Healthcare Reform to Cost Drugmakers \$105 Billion Over Decade—Leerink . . . . .	10
...Meanwhile, Biotechs May be Real Winners . . . . .	10
An Analysis of Global R&D Spending on Clinical Trials, by Phase and by Region, 2002-2016P . . . . .	11
The Global Clinical Trials Market: Global R&D Spending on Phase 1-3 Clinical Trials, 2002-2016P . . . . .	11
Global R&D Spending by Clinical Trial Phase, 2002-2016P . . . . .	11
Estimate of Global Pharmaceutical R&D Spending (Percentage) by Region . . . . .	12
Estimate of Global Pharmaceutical Clinical Trial Spending (Phases 1-3) by Region, 2009 . . . . .	12
CROs Conduct Trials 30% Faster—Business Insights . . . . .	12
More Than Two-Thirds of Large Firms Maintain/Increase R&D Spending Despite . . . . .	
Economic Crisis: Annual Booz & Company Study . . . . .	13
R&D Spending by Geographic Area, Ethical Pharmaceuticals, PhRMA Member Companies, 2008 . . . . .	14
Domestic U.S. Scientific, Professional, and Technical R&D Personnel by R&D Function, . . . . .	
Ethical Pharmaceuticals, 2008 . . . . .	15
Domestic R&D by Function, Ethical Pharmaceuticals, PhRMA Member Companies, 2008 . . . . .	15
Domestic R&D and R&D Abroad for Human-Use and Veterinary-Use Pharmaceuticals, PhRMA Member Companies, 2008 . . . . .	15
Domestic R&D by Origin of Product (Licensed-in vs. Self-originated), PhRMA Member Companies, 2008 . . . . .	15
Two in Ten New Drugs Recoup Costs—New Study . . . . .	15

U.S. Government (NIH) Funding for Medical/Clinical Research, 1995-2010 . . . . .	16
NIH Appropriations, 1995-2010P . . . . .	16
NIH Clinical Research and Clinical Trials Spending, 2003-2010 . . . . .	16
Estimates of Funding for Selected Diseases, Conditions, and Research Areas, 2007-2010 . . . . .	16
The “Net Innovation Trend” and What It Means for Big Pharmas, Biotechs, and Generics . . . . .	17
Large Cap Pharma Accounted for Two-Thirds of Healthcare Value in 2000 . . . . .	17
Biotech and Med Tech Gained at Expense of Pharma in 2008. . . . .	17
The Innovation Curve: Major Pharmaceuticals . . . . .	17
The Innovation Curve: Biotechnology. . . . .	17
An Analysis of Worldwide Prescription and OTC Drug Sales by Therapy Area, 2008-2016P. . . . .	18
WW Rx and OTC Sales by Therapeutic Area: Top 15 Categories. . . . .	18
WW Rx and OTC Sales by EvaluatePharma Therapy Area: Top 15 Categories and Total Market, 2009-2016P. . . . .	18
An Analysis of Worldwide Prescription Drug Sales, 2009-2016P . . . . .	19
Worldwide Total Prescription Drug Sales, 2002-2016P . . . . .	19
Worldwide Sales at Risk from Patent Expiration, 2002-2016P . . . . .	19
WW Prescription Drug Sales (2009/16): Top 20 Companies and Total Market . . . . .	19
An Analysis of Worldwide Prescription and OTC Sales by Technology (2002-2016):	
Biotech vs. Conventional Technology (EvaluatePharma). . . . .	20
Worldwide Prescription & OTC Sales by Technology, 2002-2016 (EvaluatePharma) . . . . .	20
Top 100 Drug Sales by Technology, 2002-2009 (EvaluatePharma). . . . .	20
An Analysis of the Sales Potential of New Drugs Approved in 2008 and 2009 (EvaluatePharma) . . . . .	21
FDA Approval Count vs. 5th Year after Launch US Product Sales (EvaluatePharma) . . . . .	21
Top 10 New Molecular Entities in 2009: Ranked on US Consensus Sales in 2014 (EvaluatePharma). . . . .	21
Top 10 New Molecular Entities in 2008: Ranked on US Consensus Sales in 2013 (EvaluatePharma). . . . .	21
Growth in Domestic U.S. Sales and Sales Abroad, Ethical Pharmaceuticals, 1970-2009 . . . . .	22
Sales by Geographic Area, Ethical Pharmaceuticals, PhRMA Member Companies, 2008 . . . . .	23
An Analysis of the U.S. Pharma Market: U.S. Prescription Drug Sales in 2009 . . . . .	24
Annual Growth Rate of U.S. Prescription Pharmaceutical Market, 1994-2010P . . . . .	24
Top 15 Therapeutic Classes by U.S. Prescription Sales, 2009 . . . . .	24
Top 15 U.S. Prescription Products by Sales, 2009 . . . . .	25
Top 15 Pharma Companies by U.S. Prescription Sales, 2009 . . . . .	25
Are Generic and Brand Drugs Equivalent? The Question That Won’t Go Away . . . . .	25
A New Look at the Global Pharmaceutical Market: North America Sets Pace in 2009 Pharma Sales . . . . .	26
Global Pharma Sales, 2002-2009. . . . .	26
Global Pharmaceutical Sales in 2009 by Region. . . . .	26
Leading Therapy Classes in 2009 Global Pharma Sales . . . . .	26
Global Pharma Sales in 2009—Leading Products. . . . .	26
Top 15 Global Drug Companies by Sales, 2009. . . . .	27
Off-Label Drug Use, Health Plans, and Market Access . . . . .	27
Top 20 Companies by Worldwide Prescription Drug Sales in 2008/2009 (EvaluatePharma) . . . . .	28
A Cost Case for Clinical Trials Outsourcing. . . . .	28
Drug Firms Play Game of “Chicken” with Greek Government . . . . .	28
Generic Drugs Have Almost Three-Quarters of Market . . . . .	28
Big Pharma Portfolio Evolution in the Post-Patent Expiry World . . . . .	29
Top 10 Selling Drugs in 2009A vs 2015E. . . . .	29
Composition of Sales by Molecular Type/Business Area in 2009A and 2015E . . . . .	30
Roche and Novartis: Being in UK Not So “NICE”. . . . .	30
Top 50 Selling Drug Products in the World, 2008 vs. 2009P. . . . .	31
Top 50 Selling Drugs in the World, 2009 vs. 2016P . . . . .	32
European Financial Crisis Could Bring “Dramatic” Pharma Industry Changes—Roche’s Schwan . . . . .	33
Re-Characterizing the Pharmerging Markets: The 17 Pharmerings to Overturn Current Pharma World Order . . . . .	34
Redefining Pharmerging Markets . . . . .	34
The Pharmerging Markets Will Be the Biggest Contributor to Global Growth from 2009-2013 . . . . .	35
Old Order Gives Way to a New World Ranking of Pharmaceutical Markets: Top 20 Projected Markets by 2013 . . . . .	35
Contribution to Drug Market by Age of Drug. . . . .	36
Percentage Contribution to the Overall Market by Age of Drug, 2002-2012E . . . . .	36
Trends in US Product Lifecycle Length: Drugs vs. Biologics . . . . .	37
Average US Lifecycles for 900 Products in Lehman Universe . . . . .	37
Global Biologic Drug/Vaccine Sales to 2012E. . . . .	37

Which Therapeutic Categories Are Growing the Fastest?: Global and US Sales Growth of Branded Drugs by Therapeutic Category, 2005-2012E .....	38
Global Drug Sales and Growth Forecasts in Major Therapeutic Areas: 2005-2012E .....	38
US Sales and Growth Forecasts—Major Therapeutic Areas, 2005-2012E .....	39
Therapeutic Categories: Drug Sales as a Percentage of Worldwide Market, 2009 vs. 2014P .....	39
Pharma Companies: Drug Sales as Percentage of Worldwide Market, 2008 vs. 2014P .....	39
How Virtual R&D Advances Will Reshape the Current R&D Model by 2020 .....	40
The Current Research Process .....	40
What the research process might look like when virtual man exists .....	41
What the research process might look like in 2020 .....	41
The Current Development Process .....	41
Model Trial .....	41
What the development process might look like in 2020 .....	42
What the regulatory process might look like in 2020 .....	43
How the R&D cost/revenue curve might look by 2020 .....	43
The Truth About Drug Innovation: Thirty-Five Summary Case Histories on Private Sector Contributions to Pharmaceutical Science .....	44
Central Private-Sector Scientific Contributions to Thirty-five Drugs/Classes .....	44
The Future of Pharma: Adjusting the Pharma R&D Model .....	45
An Opportunity Map for Pharma R&D .....	45
Large Rx Players Competing for the Same Real Estate .....	45
An Analysis of Worldwide Generic Drug Sales: Top 20 Companies in 2009 Sales .....	47
Top 20 Companies by Global Unbranded Generic Drug Sales in 2009 .....	47
Specialty and Generic Drugs Continue Rise—IMS .....	47
U.S. Generic Drug Market Outlook to 2015 .....	48
U.S. Sales of Drugs Losing Patent Protection, 2009-2015 .....	48
Percent Sales Vulnerable to Patent Expirations Through 2013 and 2015: Selected Leading Companies .....	48
Biosimilars and the Growing Threat of Biotech Generics: Estimates of the Market .....	48
Estimates of Generic Erosion at the Top 10 Pharmas, 2008 vs. 2015 .....	49
Biggest Threat to Pharma Innovation; Generics and Patent IV Challenges .....	49
Assessing Patent Risk: Industry and Company-specific Exposure to Generics, 2008-2014E .....	50
Percentage of Global Sales at Risk of Loss Over Time Through Patent Expiries, 2001-2014E .....	50
Pharma Sales at Risk of Generic Competition in 2009-2013E as a Percentage of 2008 Group Economic Sales .....	51
Biomarker Market to \$12.8bn by 2012 .....	51
A CRO Outsourcing Model to 2011 .....	52
Clinical Trial Enrollment Trends, 2004-2009 .....	52
Patients in Starting and Completing Phase II-III Trials, 2006-2009 .....	53
Patients in Starting and Completing Phase II-IV Trials, 2006-2009 .....	53
The Barclays Capital Outsourcing Model, 2005-2011 .....	54
A CRO Industry Size Model to 2015E .....	55
Getting to the Outsourced Drug Development Market in 2008 .....	55
BioPharmaceutical Industry Revenue and Year-over-Year Growth, 2003-2015E .....	55
BioPharmaceutical Industry R&D Spending and Year-over-Year Growth, 2003-2015E .....	56
CRO Addressable Market by Phase, 2003-2015E .....	57
Outsourcing Penetration Assumptions by Phase, 2003-2015E .....	57
CRO Market Size by Phase and YOY Growth, 2003-2015E .....	58
Estimates of Global Demand for Clinical Services Outsourcing, 2001-2009P .....	58
A Global CRO Market Model: A December 2009 Assessment .....	59
Estimated CRO Addressable Market, 2003-1013E .....	59
CRO Market Penetration Estimates, 2003-2013E .....	59
CRO Industry Growth to 2013 .....	60
CRO Market Overview, 2003-2013 .....	60
New Global Pharma Outsourcing Market Model to 2011 .....	61
CRO Market Opportunity, 2006E-2011E .....	61
CRO Market Opportunity by Stage .....	61
The Goldman Sachs Global R&D Outsourcing Model .....	61
A 2008 Update to the Goldman Sachs Global R&D Outsourcing Model .....	63

## *Biopharmaceuticals*

Top 100 Biotech Companies by 2009 R&D Spending . . . . .	64
R&D Spending at Selected Leading Biotechnology Companies, 2009A-2014E . . . . .	65
Biotech Bounceback? . . . . .	65
Biologics and Biotech R&D: An Analysis of PhRMA Member Companies, 2008 . . . . .	66
Biologics and Biotechnology R&D, PhRMA Member Companies, 2008 . . . . .	66
“Established” Biotech Centers Profitable for First Time in 2009—E&Y . . . . .	66
Don’t Look for Many More Big Biotechs—Burrill . . . . .	66
Biotech Sector Bounces Back in 2009: Financing Activity in Biotech Sector . . . . .	67
Total Equity Raised by Biotech, 1995-2009 . . . . .	67
Equity Investments in Biotechnology, 2009 vs. 2008 . . . . .	68
An Analysis of Global Biologics/Biotech Market: Worldwide Sales for Top Products and Top Product Classes in 2009 . . . . .	69
Top-Selling Categories of Biologic Products, 2009 . . . . .	69
Growth Rates of Top-Selling Classes of Biological Products, 2009 . . . . .	69
Top 20 Selling Biologic Products Worldwide, 2009 . . . . .	69
Follow-on Biologics: Assessments of Impact and Appropriate Exclusivity Period . . . . .	70
Estimates of/Support for Appropriate Data/Market Exclusivity for Biological Products . . . . .	70
Total World Biogenerics Market Potential . . . . .	70

## **Section 2: Products in Development**

### *Pharmaceuticals*

Worldwide Drugs in the Pipeline by Therapeutic Category as of January 2010 (IMS Health) . . . . .	71
Top 50 Drug Companies by Number of Drug Products in Development as of January 2010 (IMS Health) . . . . .	72
Top 50 Drug Companies by Number of Drug Products in Development as of March 2010 (Pharmaprojects/Pipeline) . . . . .	73
A Snapshot of the Pharma R&D Pipeline, Number of Projects by Development Phase, 1998-2010 . . . . .	74
Worldwide Active R&D Projects in Development by Stage, 1998-2010 . . . . .	74
The R&D Pipeline, 1998-2010 . . . . .	74
An Analysis of the Drug and Biotech Pipeline by Development Phase, Technology, Therapeutic Category, and Strategy (EvaluatePharma), April 2010 . . . . .	75
R&D Project Count by Current Phase (EvaluatePharma) . . . . .	75
R&D Project Count by Technology (EvaluatePharma) . . . . .	75
R&D Project Count by Therapy Area (EvaluatePharma) . . . . .	75
R&D Project Count by Strategy, Organic, Licensed (EvaluatePharma) . . . . .	75
Worldwide Prescription Drug Sales from Biotechnology in 2016: Top 10 Companies . . . . .	75
An Analysis of New Clinical Trial Starts for Drugs as Measured by Commercial IND Submissions to FDA, 2009 . . . . .	76
New FDA-Regulated Clinical Trial Starts for Drugs and Biologics/Biotechs, 1998-2009 . . . . .	76
Breakdown of CDER Divisional Workload by INDs Received in 2009 . . . . .	76
Segmentation of US Clinical Trial Starts for Drugs by Therapeutic Category, 2007, 2008, and 2009 . . . . .	77
Global New Active Substance Product Launches, 2009 . . . . .	77
An Analysis of FDA-Regulated Clinical Trial Activity for Drugs as Measured by Active INDs at Year-End 2008 . . . . .	78
Breakdown of CDER Drug Divisions’ IND Review Workload (Active as of Year-End 2008) . . . . .	78
Segmentation of FDA-Regulated Clinical Trials for Drugs by Therapeutic Category, 2008 . . . . .	78
The R&D Pipeline: A 2010 Assessment . . . . .	79
Drugs in Active Development, 1995-2010 . . . . .	79
Drug Development by World Status, 1995-2010 . . . . .	79
Measures of Pharma Industry’s New Drug Output: NME/NAS Submissions to FDA and EMEA, 1995-2009 . . . . .	80
Annual Number of Marketing Applications for New Molecular Entities/New Active Substances Filed With the FDA and EMEA, 1995-2009 . . . . .	80
Top 20 Most Valuable R&D Projects (Ranked by Net Present Value) . . . . .	81
Drug Approvals Unlikely to Rise for A While—EMEA’s Lonngren . . . . .	81
A Call for Pharmas to Exit Internal Research and Externalize Research . . . . .	82
Attrition Rate for Drug Development Is Front-end Loaded . . . . .	82
A Two-Year Reduction in Development Increases a Drug’s ROIC by c.34% . . . . .	82
Risk-Adjusted Invested Capital is Driven by Attrition Risk and Development Time . . . . .	82
Cumulative risk-adjusted Economic Value Added of an In-licensed Phase IIb Drug . . . . .	83
...Is significantly Higher than Cumulative Risk-Adjusted Economic Value Added of Internally Developed Drug . . . . .	83
Late-stage In-licensing Approximate Returns Characteristics of a Risk Reversal Option	
Trade Capping Upside and Downside Risk . . . . .	83

...As Demonstrated by the Difference in the Cumulative Risk-Adjusted Economic Value Added.....	84
TC-5214 Risk Adjusted EVA from Late-Stage In-licensing is >3 Times EVA from Internal Research.....	84
Weak Economic Arguments for Continuing Research in GI, CNS, Cardiovascular or Respiratory—Clinical Approval Success Rates by Therapeutic Class .....	84
Success Rates for In-licensed Drugs Exceed Those of Internally Discovered Drugs.....	85
Probability of Success in Each of the Clinical Phases and at Submission .....	85
Valuing Company R&D Pipelines based on NPV Analysis: Top 20 R&D Spenders .....	86
Valuing the R&D Pipeline: Pipeline NPV Minus Pharma R&D in 2009.....	86
Measures of Diversity and Novelty of Drug Targets in Active R&D Projects.....	87
Target Diversity: Number of Protein Targets Under Study in R&D Projects, 1995-2010.....	87
Percentage of Products Involving “Unproven” Targets, by Phase .....	87
The Innovativeness of the 2009 NME Approvals.....	87
The Approval Rebound Begins: ICTs vs. “Other” Drugs Approved, 1996-2009.....	87
Active Clinical Drug Development Programs Worldwide by Phase, April 2010.....	88
Number of Active Clinical Development Programs, 2010 .....	88
Total Average Number of Active Programs by Year, March 2001-April 2010 .....	88
Comparison of Annual Growth Rate—2006 vs. 2007 vs. 2008 vs. 2009 vs. 2010 .....	88
Top Therapeutic Categories by Number of Projects in Development as of March 2010 (Pharmaprojects) .....	89
Number of Drugs in Preclinical Testing, 1995-2010 .....	89
Top Therapeutic Drug Categories Worldwide by Number of Projects in Development as of January 2010 .....	89
Drug R&D Projects: Top Ten Areas of Research, 2009.....	89
Growth in the Number of Compounds in Development: A 2010 Assessment.....	90
New Compounds in Various Stages of Development, Indexed, 1995-2010.....	90
Absolute Number of New Compounds in Pharmaceutical Development: January 2007-April 2010 .....	90
Proportion of Top Pharma and Biotech Company Pipelines In-Licensed: A 2010 Assessment .....	91
Leading Pharma Companies by Pipeline Size: Percent of Pipelines In-Licensed, 2009 vs. 2010 .....	91
Selected Leading Biotech Companies by Pipeline Size: Percent of Pipelines In-Licensed, 2009 and 2010 .....	91
Number of Companies in Pharma R&D on Rise, 1998-2010.....	91
Risk-Sharing Takes Root: An Analysis of Emerging Dealmaking Trends.....	92
Alliance Volume by Therapeutic Area .....	92
Alliance Volume by Phase of Product (2007-2009) .....	92
Are Deal Up-Fronts on the Rise?.....	92
A Closer Look at 2009 Phase II and Phase III Deals .....	92
The Rise of Option-Based Licensing, 2004-2009 .....	93
2009: Earn-Outs’ Breakout Year .....	93
Companies Turning Away from Neuropharm R&D—Tracy .....	93
Pharma/Biotech Dealmaking: An Analysis of Activity in 2009.....	94
Top 10 Dealmakers in 2009.....	94
Pharma/Biotech Product and Technology Deals, 2009.....	94
Dealmaking Trends 2006-2009: Biologics vs. Small Molecules .....	95
Deal Metrics by Assets’ Stage of Development, 2001-2009 .....	95
Desperation Making Dealmaking Difficult? .....	95
New Drugs for Neglected Diseases Are on the Rise.....	96
Neglected Disease Drug Approvals, 2000-2009 .....	96
Products Currently in the Clinical Development Pipeline.....	96
Merck’s Clark on the Future for Merck, Industry.....	96
The Direction of Clinical Research: Trial Starts Signal Industry’s Direction in Six Key Therapeutic Areas, 2008-2009 .....	97
Late-Stage Oncology Trials Initiated, September 2008-August 2009 by Disease .....	97
Late-Stage Oncology Trials Initiated, September 2008-August 2009 by Company (Top 20) .....	97
Late-Stage Metabolic/Endocrinology Trials Initiated, September 2008-August 2009 by Disease.....	98
Late-Stage Metabolic/Endocrinology Trials Initiated, September 2008-August 2009 by Company (Top 20) .....	98
Late-Stage CNS Trials Initiated, September 2008-August 2009 by Disease .....	98
Late-Stage CNS Trials Initiated, September 2008-August 2009 by Company (Top 20) .....	98
Late-Stage Cardiovascular Trials Initiated, September 2008-August 2009 by Disease .....	99
Late-Stage Cardiovascular Trials Initiated, September 2008-August 2009 by Company (Top 20).....	99
Late-Stage Infectious Disease Trials Initiated, September 2008-August 2009 by Disease .....	100
Late-Stage Infectious Disease Trials Initiated, September 2008-August 2009 by Company (Top 20) .....	101
Late-Stage Autoimmune/Inflammation Trials Initiated, September 2008-August 2009 by Disease .....	101
Late-Stage Autoimmune/Inflammation Trials Initiated, September 2008-August 2009 by Company (Top 20).....	102

Total Number of New Drug Approvals Decline, But US Preferred Market for First Launch . . . . .	102
Number of Priority, Standard, and All NCEs Approved, 1984-2007 . . . . .	102
Share of NCE Approvals by Location of Original Marketing, 1987-2007 . . . . .	102
An Assessment of the Personalized Medicine Market Size, 2009-2015 . . . . .	103
Theranostics and Already Approved Drugs: What You Don't Know Can Hurt You . . . . .	104
Clinical Trials Utilizing CYP2C19 to Segment Clopidogrel Patients Before FDA Action in June 2009 . . . . .	105
Impact of FDA Labeling on Revenue Growth . . . . .	106
Hassan on Whether Mergers Hurt Innovation . . . . .	107
International Patenting of Pharmaceuticals and Biotechnology: A 2009 Assessment of Top Innovators . . . . .	108
Ranking of Top 20 Pharma/Biotech Patentees, May 2009 . . . . .	108
Therapeutic Focus in 2007 Patenting . . . . .	109
Pharma Development, Biomarkers, and Personalized Medicine . . . . .	109
Drug Makers Create Joint Database to Advance Alzheimer's Research . . . . .	109
The Emergence and Future of Companion Diagnostics: A 2009 Assessment . . . . .	110
Three Examples of Approved Drugs with Companion Diagnostics . . . . .	110
Companion Diagnostic Segments . . . . .	110
Theranostic Drugs and Diagnostics: Currently Marketed Theranostic Drugs by ATC Code and Diagnostics Utilized for Theranostic Drugs . . . . .	111
Oncology Theranostic Landscape, 2007 . . . . .	111
Pharma and Diagnostic Development Timeline . . . . .	113
New Generation of Personalized Medicine Diagnostics Command Value-Based Pricing . . . . .	113
Pharma and Biotech Company Pipelines: An Assessment of "Replacement Power," 2008 . . . . .	114
Large Pharma Replacement Power: 13 Major Companies . . . . .	114
Large Biotech Replacement Power: 7 Major Companies . . . . .	115
Pediatric Trial Activity: A 2009 Assessment . . . . .	115
Top Five Sponsors Conducting Pediatric Trials . . . . .	115
Top Five Therapeutic Areas in Pediatric Development . . . . .	115
An Assessment of Pharma Industry Pipelines: The Number and Value of Anticipated Launches to 2012e . . . . .	116
Industry Summary: Launches, Peak Sales, and NPV by Year of First Launch, 2002-2012E . . . . .	116
Launch Expectations Over Time: Comparison of Lehman's 2004-2008 Estimates . . . . .	116
Number of Drugs by Phase of Development, 2002-2008 . . . . .	117
Breakdown of R&D Portfolio by Development Stage and Potential Peak Sales, 2006-2008 . . . . .	117
Probabilities of Success for Phase 3 Drugs—2005 vs. 2008 . . . . .	117
Number of Annual New Drug Launches Projected for 58 Selected Companies in Lehman Universe, 2002-2012e . . . . .	118
Novartis Looks to Oncology and Biologics, Continues to Transform R&D Portfolio . . . . .	119
Novartis vs. Nine Leading Pharmas by Number of NMEs Approved by FDA, 2000-October 2009 . . . . .	119
The Evolution of the Novartis Clinical Development Pipeline, 2008-2010 . . . . .	119
Number of Patients Enrolled by Month, Novartis vs. Industry . . . . .	120
Cost per Completed Patient, Novartis vs. Industry . . . . .	120
Post-Genentech, Roche Pursues "Pure Pharma" Innovation and Personal Healthcare . . . . .	121
pRed Mission and gRED Research Efforts . . . . .	121
Roche's Five-Year Pipeline Ambitions . . . . .	121
Roche's Phase 3 Pipeline of NMEs, 2007-2010E . . . . .	122
Roche's Clinical Development Pipeline of NMEs by Therapeutic Area . . . . .	122
Court Rules on Legality of Gene Patents—Who Won? . . . . .	122
The "New Merck" Unveils Integrated R&D Pipeline . . . . .	123
Merck's Pipeline Strengths: Cardiovascular and Infectious Diseases . . . . .	123
The New Merck's Integrated Pipeline . . . . .	123
Merck BioVentures: Aggressive Targets . . . . .	124
AstraZeneca Restructures to Drive R&D Productivity . . . . .	125
AstraZeneca's Disease Areas of Focus . . . . .	125
New AstraZeneca Model for Prioritizing Disease Areas . . . . .	125
New AstraZeneca R&D Operating Model . . . . .	126
The AstraZeneca Pipeline, 2004-2009 . . . . .	126
AZ Discovery Productivity, 2002-2009 . . . . .	127
AstraZeneca's NME Clinical Pipeline by Therapeutic Area, January 2010 . . . . .	127
R&D Pipeline in a Product . . . . .	127
Pfizer Refocuses Pipeline Following Wyeth Merger . . . . .	128
The New Pfizer Operating Model . . . . .	128

Pfizer's New Research Organization: Separate Units for Drugs and Biologics .....	128
The New Pfizer R&D Pipeline .....	129
Pfizer's Biologics and Vaccines Development Pipeline, March 2009 vs. January 2010 .....	129
The Pfizer Clinical Pipeline: Post-Acquisition .....	129
Decoding a Genome Becomes More Affordable .....	129
Lilly All In on Innovation .....	130
Lilly's NMEs in Clinical Development, 2000-2011 .....	130
The Lilly Clinical Pipeline by Indication .....	130
Phase 2 Portfolio Success Rates: Actual and Estimated .....	131
From FIPCO to FIPNET Transition .....	131
GSK Moves Ahead on Strategic Priorities, R&D Strategies .....	132
Increase in Discovery Externalization .....	132
GSK Not Alone in Option-based Licensing Deals .....	132
GSK Shifts R&D Spend From Early- to Late-Phase Research .....	132
GSK Grows the Biopharm Pipeline, 2002 vs. 2009 .....	133
Driving Efficiencies Through Clinical Development .....	133
Re-personalization of Drug Discovery: GSK's DPUs .....	134
Only Real Innovation Need Apply—Greenwood .....	134
Witty on Striking Deals .....	134
Bristol-Myers Squibb: Moving Forward as “Truly Focused Biopharmaceutical Company” .....	135
Major Pharma: U.S. NME Approvals 2002-2009 vs. 2008 R&D Spend .....	135
BMS String of Pearls .....	135
BMS Disease Areas and Unmet Medical Needs .....	136
The BMS Pipeline by Development Phase and Disease Area .....	136
The Drug Pipeline and Attrition: A 2009 Assessment .....	137
Why Investigational Candidates Are Dropped, 2000-2008 .....	137
Top 10 Most Popular Targets in Drug Development .....	137
Novel Drugs by Phase of Development .....	137
Dearth of New Drugs an Industry Issue, Not an FDA Issue—Lilly's Paul .....	137
PhRMA's Medicines in Clinical Development Series .....	138
Analysis of Drugs in Clinical Development for Cancer by Development Status and Indication, 2009 .....	138
Analysis of Drugs in Development for Neurological Disorders by Development Status and Indication, 2008 .....	138
Analysis of Drugs in Development to Treat Rare Illnesses, 2007 .....	138
Analysis of Drugs in U.S. Clinical Development to Treat Mental Illnesses, 2008 .....	139
Analysis of Drugs in U.S. Development for Heart Disease and Stroke, 2009 .....	139
Analysis of Drugs in U.S. Clinical Development for Diseases of Aging, 2008 .....	139
Analysis of Drugs in U.S. Development for AIDS and AIDS-Related Illnesses, 2008 .....	139
Analysis of Drugs in U.S. Clinical Development to Treat Pediatric Illnesses, 2007 .....	140
Analysis of Drugs in U.S. Clinical Development for Women by Development Status and Indication, 2007 .....	140
Analysis of Drugs in U.S. Clinical Development for Diabetes and Related Conditions, 2009 .....	140
Analysis of Drugs and Vaccines in U.S. Clinical Development for Infectious Diseases, 2007 .....	140
Leading Pharmaceutical Company R&D Profiles .....	141
GlaxoSmithKline .....	141
Sanofi-aventis .....	142
Pfizer .....	143
Abbott .....	143
Johnson & Johnson .....	144
Eli Lilly .....	145
Merck .....	146
Astellas .....	146
Roche .....	146
AstraZeneca .....	148
Amgen .....	149
Bayer Schering Pharma AG .....	149
Bristol-Myers Squibb .....	150
Novartis .....	150
Development Pipelines of Selected Leading Drug Companies: Number of Products by Stage of Development, March 2010 .....	152

## *Biopharmaceuticals*

Biotech Company Development Pipelines: Number of Development Projects by Phase of Development, March 2010	153
The Pipeline for Monoclonal Antibodies: A 2009 Assessment	154
Therapeutic mAbs in Development by Phase, 1995-2009	154
The Number of Monoclonal Antibody Therapies in Development by Subtype, 1995-2009	154
Development Project Pipelines for Selected Leading Biotech Companies by Therapeutic Categories and Phases, March 2010	155
Antibiotics and the “10 by 20” Campaign	156
Biotech: Entering a New Product Cycle?	157
Long Gaps Between Product Launches Are Common: Six Leading Biotechs, 1985-2010E	157
Cumulative Number of Biotechnology Products Approved by the FDA, 1993-2009	157
Entering Another Cycle of Growth	157
Biotechnology Products as a Percentage of Total R&D Pipeline: Various Estimates	158
Biotechnology Products as a Percentage of the Total R&D Pipeline, 1995-2009	158
R&D Project Count by Technology	158
Molecular Diagnostics: An Early Winner in Personalized Medicine Market	158
Analysis of Biotechnology Medicines and Vaccines in US Clinical Development by Development Status and Therapeutic Category, 2008	159
A 2008 Assessment of Gene Therapy Trials	159
Gene Therapy Trials by Phase, 2008	159
Top Medical Conditions Targeted by Gene Therapy Trials	159
A 2008 Analysis of the Mid- and Late-Stage R&D Pipeline: Size, Developer Type, Indications, and Success Rates	160
Number of Drugs in Phase 2-Pre-Registration by Developer Type	160
Number of Indications per Drug in Phase 2-Pre-Registration by Developer Type for Select Years	160
Likelihood of Approval by Phase for Large Company Products	160
Likelihood of Approval by Phase for Small Company/Institution Products	160
Trends in the Clinical Development and Approval of Peptides: A 2009 Assessment	161
Average annual number of peptide therapeutics entering study during seven time periods	161
Therapeutic categories for peptide candidates entering study in three time periods	161
Mean clinical and US approval phases for peptide new chemical entities approved after 1992	162

## **Section 3: Drug Development Costs/Complexity, Development Time, and Success Rates**

### *Costs/Complexity*

Measures of Clinical Trial Costs, 2007-2009 (TTC)	163
Mean Cost per Patient in Clinical Trials by Clinical Phase, Worldwide, 2007-2009	163
Mean Cost per Patient in Clinical Trials by Therapeutic Area, 2007-2009	163
Mean Patient Reimbursement Per Visit in Clinical Trials, 2007-2009	163
Mean Patient Reimbursement Per Visit in Clinical Trials by Phase, Worldwide, 2007-2009	163
Mean Patient Reimbursement Per Visit in Clinical Trials by Therapeutic Area, Worldwide, 2007-2009	163
Indexed Measures of Clinical Trial Costs, 2006-2009 (TTC)	164
Index of Mean Cost per Patient in Clinical Trials by Clinical Phase, 2007-2009	164
Index of Mean Cost per Patient in Clinical Trials by Country/Region	164
Index of Mean Cost per Patient in Clinical Trials by Therapeutic Area, 2007-2009, Phase I-IV	164
Mean Site Fees per Clinical Study by Phase, 2007-2009	164
Measures of Clinical Trial Costs per Patient, 2007-2009 (TTC)	165
Index of Mean Cost per Patient in Clinical Trials by Clinical Phase, US, 2007-2009	165
Index of Mean Phase I Cost per Patient in Clinical Trials by Therapeutic Area, US, 2007-2009	165
Index of Mean Phase II Cost per Patient in Clinical Trials by Therapeutic Area, US, 2007-2009	165
Index of Mean Phase III Cost per Patient in Clinical Trials by Therapeutic Area, US, 2007-2009	165
Index of Mean Phase IV Cost per Patient in Clinical Trials by Therapeutic Area, US, 2007-2009	165
Measures of Clinical Study Complexity, 2007-2009 (TTC)	166
Index of Clinical Study Complexity by Trial Phase, Worldwide, 2007-2009	166
Index of Clinical Study Complexity by Country/Region, Phase I-IV, 2007-2009	166
Index of Clinical Study Complexity by Year, Phase I-IV, Worldwide, 2007-2009	166
Index of Clinical Study Complexity by Therapeutic Area, Phase I-IV, Worldwide, 2007-2009	166
Recent Estimates of the Cost of Developing New Drugs, 2010	167
Biomedical Research and Development Price Index, 1980-2015P	168
Selected Health Care Inflation Data, 1999-2009	168

Relative Clinical Study Costs: U.S., Western Europe, Eastern Europe, and Asia . . . . .	169
Relative per Visit Grant Costs in Selected Western European Countries. . . . .	169
Relative per Visit Grant Costs in Selected Eastern European Countries . . . . .	169
Relative per Visit Grant Costs in Various Asian Countries . . . . .	169
Indian vs. U.S. Procedure and Professional Fees . . . . .	170
EDC Market Estimates for 2010 . . . . .	170
Analysis of Overhead Costs for U.S.-based Institutions Conducting Clinical Trials . . . . .	170
An Analysis of Clinical Trial Protocol Complexity and Execution Burden by Phase and Therapeutic Area . . . . .	171
Protocol Complexity and Burden Across All Therapeutic Areas and Phases. . . . .	171
Highest Growth Areas in Complexity and Execution Burden by Clinical Trial Phase, 2002-2007. . . . .	171
Therapeutic Areas with the Highest Number of Phase I Procedures, 2002-2007. . . . .	171
Therapeutic Areas with the Greatest Complexity and Work Burden for Phase II Protocols, 2002-2007 . . . . .	171
Therapeutic Areas with the Highest Average Work Burden per Phase III Protocol, 2002-2007. . . . .	172
Top Therapeutic Areas with the Greatest Complexity and Work Burden for Phase IV Protocols, 2002-2007. . . . .	172
A Hidden Cost of Head-to-Head Trials: Active Control Drugs Aren't Cheap . . . . .	172
Activating Investigative Sites in a Staggered Process: Challenges and Solutions . . . . .	173
A Typical Site Activation Curve by Using Staggered Site Activation . . . . .	173
First Quartile of Country Activation Cycle Times . . . . .	173
Altered Site Activation Curve by Activating All the Sites Spontaneously. . . . .	174
Study Start Up Resource Curve in a Staggered Site Activation . . . . .	175
Study Start Up Resource Curve in an "All Out" Site Activation . . . . .	175
Speed, Not Costs, Driving Factor for Global Trials . . . . .	175
A 2009 Assessment of U.S. Clinical Research . . . . .	176
Ongoing U.S. Clinical Trials: By Interventions Being Tested . . . . .	176
Clinical Trials Breakdown by Phase and Enrolled Subjects . . . . .	176
Ongoing U.S. Clinical Trials: Number of Trials and Subjects Across Four Therapeutic Indications . . . . .	176
Phase II-IV Trials and Subjects by Phase and Indication for Eight Therapeutic Areas . . . . .	177
Summary of Key Findings. . . . .	178
Drug Delivery/Reformulation Deals Accelerate . . . . .	178
Biotech Products Dominate Oncology Pipeline—Business Insights . . . . .	178
Three Countries Dominate Phase I Market. . . . .	178
Why Individuals Participate in Clinical Trials . . . . .	179
Factors Impacting Study Participation. . . . .	179
How U.S. Patients Learn About Clinical Trials . . . . .	179
Sites Struggle During Downturn in 2009 Research Starts . . . . .	179
Shifting Share of Clinical Projects. . . . .	179
Valuing Medicines: How the UK's NICE Measures the Effectiveness and Cost Effectiveness of New Treatments . . . . .	180
How a QALY is Calculated. . . . .	180
In the U.S., Cost Threshold Much Lower . . . . .	180
How Scientific Advances and New Drug Approvals Raise the Bar for New Clinical Trials and Approvals: An Oncology Case Study . . . . .	181
New Drugs Developed with Standard Regimen: Regulatory and Clinical Hurdles are Raised with Each New Approved Regimen . . . . .	181
The Statistical Dilemma. . . . .	181
The Limited Utility of Biomarkers: A 2008 Assessment of Biomarkers in Early Cancer Drug Development . . . . .	182
Biomarkers and Surrogate Endpoints are Often Confused . . . . .	182
Biomarkers Have Much Appeal in Expediting Cancer Drug Development . . . . .	182
However, Biomarkers Don't Offer an Easy Solution . . . . .	182
U.S. Clinical Study Sites Rate Clinical Trial Sponsors: A 2009 Assessment. . . . .	183
Highest Frequency as Top 3 Rated Sponsor Across 29 Relationship Attributes . . . . .	183
Quality of General Project Management . . . . .	183
Quality of Staff Professionalism . . . . .	184
Quality of Workstyle . . . . .	184
Quality of the Study Initiation Process . . . . .	184
Quality of Ongoing Study Support . . . . .	184
Up to a Third of Clinical Data Wasted—Getz . . . . .	184
Where Today's Clinical Trials Are Being Conducted: A Study of New FDA-Regulated Studies in 2009 . . . . .	185
Number of Investigators Signing 1572s Annually for FDA-Regulated Clinical Trials, 1995-2009 . . . . .	185
Number of Investigators Signing 1572s in Selected Countries: Year-over-Year Percentage Increase/Decrease . . . . .	185

Number of Investigators Completing 1572s to Participate in FDA-Regulated Clinical Studies by Country in 2009 . . . . .	186
Clinical Trials by Region and Phase, 2006-2009 (PAREXEL Consulting) . . . . .	187
Worldwide Clinical Trials, as first entered into ClinicalTrials.gov, in 2009 . . . . .	187
Worldwide Clinical Trials First Entered in Each Calendar Year, 2006-2009. . . . .	187
Phase IV Clinical Trials, as first entered into ClinicalTrials.gov, in 2009 . . . . .	187
Phase III Clinical Trials, as first entered into ClinicalTrials.gov, in 2009 . . . . .	188
Phase II Clinical Trials, as first entered into ClinicalTrials.gov, in 2009 . . . . .	188
Phase I Clinical Trials, as first entered into ClinicalTrials.gov, in 2009 . . . . .	188
Clinical Trial Enrollment Across Key Countries/Regions . . . . .	189
The Reluctant American Trial Participant . . . . .	189
Where Are Clinical Trials Being Conducted? Follow the Inspections . . . . .	190
CDER-DSI International Clinical Investigator BIMO Inspections, FY2009 . . . . .	190
EMA GCP Inspections Related to the Centralized Procedure: Total GCP Inspections per Country, 1997-2009 . . . . .	190
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2009 . . . . .	191
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2003-2009. . . . .	191
Clinical Trial Enrollments for Selected NMEs Approved in 2009 . . . . .	191
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2008 . . . . .	192
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2000-2008. . . . .	192
Clinical Trial Enrollments for Selected NMEs Approved in 2008 . . . . .	192
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2007 . . . . .	193
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2000-2007. . . . .	193
Clinical Trial Enrollments for Selected NMEs Approved in 2007 . . . . .	193
Site Activation as the Driver to Patient Enrollment: A 2008 Assessment . . . . .	194
Demographics of Clinical Trial Populations: A Look at NIH Trials, 2009 . . . . .	196
Benchmarking the Regulatory Affairs Function . . . . .	197
Annual Company Activity, 2008. . . . .	197
Median Major Project Volume per Company in 2008 . . . . .	197
Regulatory Affairs Function Structure, 2008 . . . . .	197
The Changing Clinical Investigator Landscape: A 2009 Assessment. . . . .	198
Number of Individual Principal Investigators, US-based and Non-US-based . . . . .	198
Global Distribution of Total FDA-Regulated Principal Investigators, 1997-2008 . . . . .	198
Snapshot of the FDA-Regulated PI Landscape . . . . .	198
Number of Principal Investigators per Active IND, 1997-2007 . . . . .	198
Mean Numbers of Patients per NDA, 1997-2007 . . . . .	199
The Case for New Drugs and Better Predictive Biomarkers. . . . .	199
Average Per-Patient Clinical Trial Costs: A 2008 Assessment. . . . .	200
Average Per-Patient Clinical Trial Costs by Phase . . . . .	200
Mean Phase 1 Per-Patient Clinical Trial Costs, by Therapeutic Area, US . . . . .	200
Mean Phase 2 Per-Patient Clinical Trial Costs, by Therapeutic Area, US . . . . .	200
Mean Phase 3 Per-Patient Clinical Trial Costs, by Therapeutic Area, US . . . . .	200
Mean Phase 4 Per-Patient Clinical Trial Costs, by Therapeutic Area, US . . . . .	200
A Market Model for EDC in Clinical Trials . . . . .	201
Percentage of Trials Using EDC, Today vs. in Three Years. . . . .	201
Electronic Data Capture (EDC) Market Model, 2006E-2012E. . . . .	201
Estimates on U.S. Electronic Data Capture Adoption. . . . .	202
U.S. Electronic Data Capture Adoption, 2003-2012. . . . .	202
Optimizing and Supporting Remote Data Capture . . . . .	203
Competing for Clinical Investigators: Numbers of Trials vs. Investigators, 2000-2009 . . . . .	203
Laptop Provisioning Rates by Clinical Trial Region. . . . .	203
Active Clinical Trials by Phase and Country/Region: A 2008 Analysis . . . . .	204
Clinical Studies Openly Recruiting by Phase and Region . . . . .	204
Number of Clinical Trials Initiated Annually for U.S. Submissions: FDA Estimates . . . . .	204
European Clinical Trial Sites Rate Pharma Sponsors . . . . .	205
Top Rated Sponsors in Europe . . . . .	205
Average 2008 Rating for the Typical Sponsor in Europe . . . . .	205
Factors That Could Best Prevent Future Delays . . . . .	205
General Project Management Attributes . . . . .	206
Quality of Staff Professionalism . . . . .	206
Quality of the Grant Payment Process. . . . .	206

New Drug Development Spending and Costs: A 2008 Analysis . . . . .	207
R&D Expenses Regressions. . . . .	207
R&D Expenses by Therapy Area for All Phases. . . . .	207
Pharma IT Spending Estimates . . . . .	208
Electronic Health Records: Low Penetration to Date . . . . .	208
An Analysis of Ways to Reduce Central Recruitment Costs . . . . .	209
Probability of Randomizing Relative Average . . . . .	209
Price Per Randomized for an Average Study by Recruitment Timeline. . . . .	209
Price per Randomized for an Average Study by FOV Rate . . . . .	209
Assessing the Cost to Develop a New Biotech Product . . . . .	210
Pre-Approval Cash Outlays and Time Costs per Approved New Biopharmaceutical . . . . .	210
Pre-Approval Cash Outlays per Approved New Molecule . . . . .	210
Pre-Approval Capitalized Cost per Approved New Molecule: Biotech vs. Pharma. . . . .	210
Capitalized Preclinical and Clinical Period Costs per Investigational Biopharmaceutical Compound . . . . .	210
Estimating the Cost of New Drug Development: Is It Really \$802 Million. . . . .	211
Average Out-of-Pocket Clinical Costs for Investigational Compounds . . . . .	211
Average Phase Time and Clinical Capitalized Costs for Investigational Compounds . . . . .	212
Capitalized Preclinical, Clinical, and Total Cost per New Drug, in Millions of 2000 Dollars . . . . .	212
Probability of Market Entry, Durations, and Costs for New Drugs by Firm . . . . .	213
Probability of Market Entry, Durations, and Costs for New Drugs, by Disorder and Primary Indication. . . . .	214
Estimates of Nonclinical Study Costs and Durations . . . . .	215
The Phase I Clinical Study Market: A 2007 Assessment . . . . .	216
Phase I Still Stands Out: Projected Spending by Phase (U.S. \$ in billions). . . . .	216
The Phase IIIb/IV Market: A 2006 Assessment . . . . .	217
Spending on Various Drug Development Phases, 2005-2009p . . . . .	217
The Central Laboratory Market: A 2006 Assessment . . . . .	218
Projected Central Laboratory Market, 2004-2009. . . . .	218
2005 Revenue from Companies with Central Laboratory Services . . . . .	218
Clinical Trial Laboratory Services Market Share . . . . .	218
<i>Development Time</i>	
Analysis of U.S. New Drug Development Process by Average Time to Complete Each Phase of Product Development, 2010 . . . . .	219
FDA Review Times for Drugs and Biologics: A 2009 Comparison. . . . .	220
Average Approval Times for New Biotech Therapies, 1996-2009. . . . .	220
Average Approval Times for Biotech Drugs and Biologics, 1996-2009 . . . . .	220
Median Approval Times for Biotech Drugs and Biologics, 1996-2009 . . . . .	221
Development Times for Biotech Products Lengthen: A 2010 Analysis . . . . .	221
Phase Lengths for FDA-Approved Novel Recombinant Proteins and mAb Therapeutics, 1982-2009 . . . . .	221
Reasons and Possible Solutions for Clinical Study Delays: A 2009 Assessment of Site Perceptions . . . . .	222
Factor Most Often Causing Study Delays . . . . .	222
Factors That Could Best Prevent Future Delays . . . . .	222
Enrollment Delays: U.S., Europe, Canada, Asia-Pacific, and Latin America . . . . .	222
Marketing Exclusivity Periods for First-in-Class Drugs: A 2009 Assessment . . . . .	223
Period of Marketing Exclusivity for First Entrants to a Therapeutic Class . . . . .	223
Average Time in Years to Market Entry for Second and Third Follow-on Drugs . . . . .	223
FDA Ratings of Therapeutic Significance for Follow-on Drugs Approved in the U.S., 1960-2007 . . . . .	223
Share of Therapeutic Classes with at Least One Follow-on Drug with Development Phase Initiated Prior to First-in-Class Approval . . . . .	224
Share of Follow-on Drugs with Development Phase Initiated Prior to First-in-Class Approval . . . . .	224
Share of Follow-on Drugs Approved in the U.S., 1970-2007. . . . .	224
Current State of Accelerated Approval for Oncology Drugs a “Disappointment”—New Study . . . . .	224
New Drug Clinical and Approval Times: A 2008 Assessment. . . . .	225
Clinical and Approval Times, 1984-2007 . . . . .	225
Clinical Phases for Priority and Standard NCEs Approved 1984-2007 . . . . .	225
Clinical Phases for NCEs Approved 1999-2007 by Therapeutic Area. . . . .	225
Clinical and Approval Times by Therapeutic Class, 2005-2007 . . . . .	225
The FDA’s Fast Track Program: A 2008 Assessment . . . . .	226
Clinical and Approval Phases for Fast Track New Chemical and Biological Entities, Fast Track vs. All Drugs . . . . .	226

Therapeutic Categories of Drugs Obtaining Fast Track Designations, 1998-2007 . . . . .	226
Reasons for Terminating Fast Track Candidates, 1998-2002 vs. 2003-2007 . . . . .	226
Phase Transition Probabilities for Fast Track Candidates, 1998-02 and 2003-07 . . . . .	227
Clinical Trial Cycle Times: Planned Timelines vs. Actuals . . . . .	227
Percentages of Planned Timelines That Trials Exceeded by Phase . . . . .	227
The FDA on Study Initiation Delays . . . . .	227
The Factors Associated with Multiple FDA Review Cycles and Approval Phase Times: A 2009 Study . . . . .	228
Mean US Approval Phase Times by Number of Review Cycles for NDA/BLAs Submitted FY1996-2006 . . . . .	228
Total Approval Phase for Drugs with NDAs or BLAs Submitted FY1996-FY2006 . . . . .	228
Number of FDA Review Cycles for Approved Drugs by Therapeutic Class . . . . .	229
Distribution of FDA Review Cycles for Approved Drugs by Priority Rating for NDA/BLAs Submitted FY1996-FY2006 . . . . .	229
Percent of Single-Cycle Approvals for Products by Regulatory Characteristic and FDA-Sponsor Interaction for NDA/BLAs Submitted FY1996-FY2006 . . . . .	229
Mean Total FDA Review and Sponsor Response Times and Shares for NDAs and BLAs Submitted FY1996-FY2006 . . . . .	230
New Drug Development Times: A 2007 Analysis . . . . .	231
Mean Clinical and Approval Times: 1994-2006 . . . . .	231
Mean Clinical and Approval Phase Lengths by Therapeutic Class, 2002-2006 . . . . .	231
Cancer Therapy Development Times vs. Other Drugs: A 2007 Study . . . . .	231
Clinical and FDA Approval Phases for New Cancer Therapeutics . . . . .	231
The FDA's Fast Track Program: Effect on Review Time and Approval Success . . . . .	232
Number and Total Approval Time (in months) of Approved NDAs and BLAs, by Fiscal Year of Submission, and by Review Procedure . . . . .	232
Delays in Study Enrollment Timelines: A 2007 Assessment . . . . .	233
Distribution of Delays in US Site Enrollment Timelines . . . . .	233
Distribution of Delays in Site Enrollment Globally: US, Europe, Latin America, and Asia Pacific . . . . .	233
Factor Most Often Causing Study Delays . . . . .	233
The Speed Demons of Drug Development: Achieving Revenue Gains and Cost Savings . . . . .	234
Fastest Development Companies: Median Clinical Development and Regulatory Cycle Times, 2000-2005 . . . . .	234
Median Time from IND Filing to NDA Approval for Nine Therapeutic Areas, 2000-2005 . . . . .	234
Median Clinical Development Time and Regulatory Cycle Times: All Companies vs. Fastest 10 Companies . . . . .	234
Standard Deviations and Coefficients of Variation for Drugs Approved Between 2000 and 2005 . . . . .	234
Fastest vs. Slowest Firms: Percentage of Terminated Projects by Phase, 1994-2005 . . . . .	235
Drugs of Fastest vs. Slowest Companies: Comparative Development and Regulatory Cycle Times and Revenue Advantage, 2000-2005 . . . . .	235
Biopharmaceutical Development Times: A 2007 Analysis . . . . .	235
Mean Biopharmaceutical Development Times: Clinical Phase, Approval Phase, and Total Phase Lengths, 1982-2006 . . . . .	235
Development Times for Biotech vs. Drug Products: A 2006 Study . . . . .	236
Clinical Development and Approval Times: Biopharmaceuticals vs. Drugs . . . . .	236
Time Consumed by Various Clinical Trial Activities . . . . .	236
Study Sites' Perceptions on Reasons for Study Delays . . . . .	236
Factor Most Often Causing Clinical Study Delays . . . . .	236
Clinical and Approval Timelines for Drugs Approved 1984-2004 . . . . .	237
Clinical and Approval Phases for New Drugs, 1984-2004 . . . . .	237
Mean Clinical Phase Times for Priority and Standard NCEs Approved, 1984-2004 . . . . .	237
Mean FDA Approval Times for Standard and Priority NCEs, 1984-2004 . . . . .	237
Mean Clinical Phase Times for NCEs Approved by Therapeutic Area, 1996-2004 . . . . .	237
Mean Clinical and Approval Phase Lengths by Therapeutic Class, 2002-2004 . . . . .	238
Share of NCE Approvals by Location of Original Marketing, 1987-2004 . . . . .	238
Number of NCE Approvals, 1984-2004 . . . . .	238
Are Development Times for Pharmaceutical Companies Increasing or Decreasing? . . . . .	239
Sample of Development Times for 25 Drugs . . . . .	239
Pharmaceutical Development Times, by Category . . . . .	240
Total Post-IND Development Period, Clinical Trial Period, and Regulatory Review Periods, by Year of NDA Approval, 1992-2001 . . . . .	241
Total Post-IND Development Period, Clinical Trial Period, and Regulatory Review Period, by Year of IND Filing, 1985-1995 . . . . .	242

The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade After Passage of PDUFA	243
Mean NCE Clinical, Approval, and Total Phase Lengths for NCEs Approved in 1999, 2000, and 2001	243
Median Clinical and Approval Phases for New Chemical Entity Approvals in 1999, 2000, and 2001	243
Mean Clinical and Approval Phases in Years for NCEs Approved in Each of Last Six Three-Year Periods	243
Mean Clinical and Approval Phases for NCEs Grouped by Therapeutic Classes	244
Mean Clinical Phases in Years for NCEs Grouped by Therapeutic Class in Each of the Last Three-Year Periods	244
Mean Clinical, Approval, and Total Phases in Years for NCEs Approved in 1999-2001 and Designated as Accelerated Approval, Fast Track Approval, or Both, Compared with Those for All Other NCEs and with Orphan Approvals	244
Percentage of NCEs First Approved in the United States and Those with Various Periods of Prior Foreign Marketing	245
Percentage of NCEs First Approved in the United States, and Those with One or More Years of Prior Foreign Marketing, in Each of the Last Five Three-Year Periods	245
<i>Success Rates</i>	
R&D Attrition Rates: Commonly Cited and Emerging Benchmarks	246
Analysis of Reported Reasons for Drug Discontinuations, 2000-2008	247
Reported reasons for drug discontinuations, 2000-2008	247
The Drug Pipeline and Attrition: A 2009 Assessment	247
Why Investigational Candidates are Dropped, 2000-2008	247
Comparative Success Rates for Self-Originated/Licensed-in and Small/Large Molecule Drugs: A 2010 Analysis	248
Phase Transition Probabilities and Clinical Approval Success Probabilities by Compound Source (Compounds First Tested in Humans from 1993-2004)	248
Phase Transition Probabilities and Clinical Approval Success Probabilities by Type of Compound, for Self-Originated Compounds First Tested in Humans from 1993 to 2004	248
New Drug Success Rates for Top 50 Pharma Companies: A 2009 Study	249
Share of Compounds Entering Clinical Testing, 2003-2007	249
Share of Compounds Entering Clinical Testing by Therapeutic Area	249
Phase Transition Probabilities for Self-Originated Drugs of Leading Firms	249
Phase Transition Probabilities for Relatively High Success Rate Classes, 1993-2004	249
Phase Transition Probabilities for Relatively Low Success Rate Classes, 1993-2004	250
Clinical Approval Success Rates by Therapeutic Class, 1993-2004	250
Roche Makes Progress on Early-Stage Attrition	250
Phase 0 Attrition Rate Trends, 2001-2008	250
Phase 1 Attrition Rate Trends, 2001-2008	250
Are Fewer NMEs Gaining FDA Approval?	251
Approval Rate Trends for Priority NMEs by PDUFA Submission Cohort	251
Approval Rate Trends for Standard NMEs by PDUFA Submission Cohort	251
FDA Approvals and Phase III Failures: Pharma vs. Biotech	251
Why Lehman Sees Phase 3 Success Rates Falling	252
Probabilities of Success for Phase 3 Drugs—2005 vs. 2008	252
Tougher Safety Standards Today?	252
Attrition Rates and Transition Probabilities for Fast Track Drugs: A 2008 Assessment	253
Reasons for Terminating Fast Track Candidates, 1998-2002 vs. 2003-2007	253
Phase Transition Probabilities for Fast Track Candidates, 1998-02 and 2003-07	253
Attrition Rates in Drug Development Phases	253
A 2008 Analysis of Approval Success Rates by Product Type and Novelty	254
NME Success Rates by Compound Type, 1997-2007	254
NME Success Rates by Target Type, 1997-2007	254
Product Type and Target Novelty, 1997-2008	254
NME Success Rates by Compound Type, 2002-2007	254
NME Success Rates by Target Type, 2002-2007	254
Product Type and Target Novelty, 2002-2007	254
A 2008 Analysis of the Mid- and Late-Stage R&D Pipeline: Size, Developer Type, Indications, and Success Rates	255
Number of Drugs in Phase 2-Pre-Registration by Developer Type, 1997-2007	255
Number of Indications per Drug in Phase 2-Pre-Registration by Developer Type for Select Years, 1997-2007	255
Likelihood of Approval by Phase for Large Company Products, 2000-2007	255
Likelihood of Approval by Phase for Small Company/Institution Products	255

Emerging Success Rates for New Cancer Therapies, 1990-2006 . . . . .	256
New Cancer Therapeutics and Vaccines Entering Clinical Study, 1993-2006 . . . . .	256
Clinical Phase Transition Probabilities for Cancer Therapeutic Candidates . . . . .	256
An Analysis of Late-Stage Success Rates: Biotech Products versus Pharmaceuticals . . . . .	257
Success Rates of Late-Stage Clinical Trials in Biotechnology, 1995-2008 . . . . .	257
FDA Actions on Biotechnology Product Applications by Nature of Action, 1995-2009 . . . . .	257
Probability of Success to Market for New Active Substances by Origin: Self-Originated vs. Licensed-in . . . . .	257
Kola on Emerging Attrition Rate Trends, 2007 . . . . .	258
Estimates of Drug Success Rates: Unprecedented vs. Precedented Molecules . . . . .	258
Drug Success Rates: Unprecedented vs. Precedented Molecules . . . . .	258
Success to Market Rates for New Active Substances: Comparison of Chemical Entities and Biotech Products . . . . .	259
Probability of Success to Market for New Active Substances: Comparison of Therapeutic Areas . . . . .	259
Can the Pharmaceutical Industry Reduce Attrition Rates? . . . . .	260
Success Rates by Therapeutic Area . . . . .	260
Success Rates from First-in-Man to Registration . . . . .	260
Success Rates by Stage of Development . . . . .	260
Reasons for Attrition . . . . .	261

## Section 4: Regulatory/FDA Statistics

### *INDs*

Number of IND Submissions, 1982-2009 . . . . .	263
Breakdown of Drug Divisions' Active IND Review Workload as of Year-End 2009 . . . . .	263
Selected FDA Drug-Related Workload Metrics for Recent 12-Month Period . . . . .	263
Breakdown of CDER Divisions' Workload by INDs Received in 2009 . . . . .	264
CDER Holds on Commercial IND Submissions, 1990-2009 . . . . .	264
Clinical Holds on Commercial IND Submissions by Division, 2009 . . . . .	264

### *NDA*s

Number of NDAs Pending at the Close of the Calendar Year, 1983-2009 . . . . .	265
Breakdown of Drug Divisions' Pending NDA Review Workload, Year-End 2009 . . . . .	265
Breakdown of Drug Divisions' Workload by NDAs Received in Fiscal Year 2009 . . . . .	265
Breakdown of Divisions' Workload by Pending NDA Supplements, Year-End 2009 . . . . .	266
CDER Refusal-to-File (RTF) Actions by Year, 1994-2009 . . . . .	266
Key Drug Submission and Approval Statistics, 1993-2009 . . . . .	267
Number of NME Approvals and Approval Times, 1984-2009 . . . . .	267
NME Review Time Ranges, 1995-2009 . . . . .	268
Priority/Standard NME Review Gap, 1995-2009 (in months) . . . . .	268
Median Approval Times for All NMEs by Calendar Year, 1986-2009 . . . . .	268
Average NME Review Times in Months by CDER Division, 2005-2009 . . . . .	269
Average NME Review Times in Months by CDER Division, 1993-2004 . . . . .	270
A 2009 Analysis of CDER First-Cycle Approval Rates for NDAs, FY1996-FY2008 . . . . .	271
First-Cycle Review Outcomes for NMEs, FY2000-FY2008 Submission Cohorts . . . . .	271
Number of NDAs and NMEs Approved by Year, 1984-2009 . . . . .	272
NMEs Approved Based on Therapeutic Potential, 1985-2009 . . . . .	272
Percent of All Approved NDAs and NMEs Receiving Priority Review Status, 1996-2009 . . . . .	272
CDER's Priority NME Approvals by Class of Drug, 1995-2009 . . . . .	272
An Analysis of Review Cycles to Approval for New Drugs . . . . .	273
Summary Cycle to Approval Statistics for 2005-2009-Approved NMEs . . . . .	273
Distribution of Review Cycles to Approval, 2005-2009 . . . . .	273
The First Cycle Review Imperative, 2006-2009 . . . . .	274
Risky Biomedical Research Needs Appropriately Aligned Rewards—Study Authors . . . . .	274
FDA Review Times for Drugs and Biologics: A 2009 Comparison . . . . .	275
Average Approval Times for New Biotech Therapies, 1996-2009 . . . . .	275
Average Approval Times for Biotech Drugs and Biologics, 1996-2009 . . . . .	275
Median Approval Times for Biotech Drugs and Biologics, 1996-2009 . . . . .	276
U.S. Orphan Drug Act: Rare Disease Stimulator or Commercial Opportunity? . . . . .	276
A Closer Look at the FDA's 50 Fastest Drug Approvals, 1963-2009 . . . . .	277
A Comparison of FDA vs. EMEA Drug Approval Times, 2000-2005 . . . . .	279
Mean Approval Times for New Substances Approved by EMEA and FDA, 2000-2005 . . . . .	279

Time from Approval in First Market to Approval in Second Market . . . . .	279
EU vs. US Approval Time for Orphan Drugs . . . . .	279
U.S. New Drug Approvals of 2009: NDA Review Times by Drug . . . . .	280
U.S. New Drug Approvals of 2008: NDA Review Times by Drug . . . . .	280
U.S. New Drug Approvals of 2007: NDA Review Times by Drug . . . . .	281
U.S. New Drug Approvals of 2006: NDA Review Times by Drug . . . . .	281
U.S. New Drug Approvals of 2005: NDA Review Times by Drug . . . . .	281
U.S. New Drug Approvals of 2004: NDA Review Times by Drug . . . . .	282
U.S. New Drug Approvals of 2003: NDA Review Times by Drug . . . . .	283
U.S. New Drug Approvals of 2002: NDA Review Times by Drug . . . . .	283
U.S. New Drug Approvals of 2001: NDA Review Times by Drug . . . . .	284
U.S. New Drug Approvals of 2000: NDA Review Times by Drug . . . . .	285
U.S. New Drug Approvals of 1999: NDA Review Times by Drug . . . . .	286
U.S. New Drug Approvals of 1998: NDA Review Times by Drug . . . . .	287
U.S. New Drug Approvals of 1997: NDA Review Time for Each Drug . . . . .	288
U.S. New Drug Approvals of 1996: NDA Review Time for Each Drug . . . . .	289
U.S. New Drug Approvals of 1995: NDA Review Time for Each Drug . . . . .	290
U.S. New Drug Approvals of 1994: NDA Review Time for Each Drug . . . . .	291
U.S. New Drug Approvals of 1993: NDA Review Time for Each Drug . . . . .	292
U.S. New Drug Approvals of 1990, 1991, and 1992: NDA Review Times for Each Drug . . . . .	293
An Analysis of the Factors Associated with First-Cycle Approvals: A 2008 Update . . . . .	295
Approval Rate vs. Novelty and Indication . . . . .	295
First-Cycle Approval Rate by Application Type . . . . .	295
Effect of Pre-NDA/BLA Meetings and Timing on Approval Rate for FY2005-FY2007 Cohort . . . . .	295
Major Deficiencies Cited in First Action Letter of Multi-Cycle Applications by Category for FY2002-FY2007 Cohort . . . . .	297
Single-Cycle Approval Rates by Sponsor Experience . . . . .	297
Approval Rate vs. Sponsor Type and Origin . . . . .	297
An Analysis of FDA's Fast Track Initiative, 2008 . . . . .	298
Industry's Fast Track Designation Requests to CDER, FY1999-FY2007 . . . . .	298
CDER's Fast Track Program Activity . . . . .	298
CBER's Fast Track Program Activity . . . . .	298
Remembering the Good Old Delays . . . . .	298
Safety-Based Drug Marketing Withdrawals in the United States, 1980-2009 . . . . .	299
CDER Safety-Based Drug Withdrawals: Pre-PDUFA vs. PDUFA Era . . . . .	300
Postmarketing Study Commitment Trends for New Drugs: An Analysis of NMEs Approved in 2009 . . . . .	300
Percent of NMEs Approved with Postmarketing Commitments, 2001-2009 . . . . .	300
Postmarketing Study Requirement Trends in the U.S., Europe, and Japan: A 2008 Assessment . . . . .	301
Average Number of PMCs per Approval by Region . . . . .	301
Types of Postmarketing Studies Requested . . . . .	301
Timing of Agreement between Sponsor and Regulatory Agency on Nature and Design of Studies . . . . .	301
Orphan Drug Activity Continues to Hover Near Record Levels . . . . .	302
Orphan Drug Designation and Approval Statistics, 1990-2009 . . . . .	302
Prevalence of Orphan Drugs in CDER's NME Approvals, 2001-2009 . . . . .	302
NDA's Approved Under CDER's Accelerated Approval Program, 1992-December 2009 . . . . .	303
<i>Biologics</i>	
Summary of CBER Actions in 2009 . . . . .	304
Key CBER Review Statistics for 2008 . . . . .	304
CBER's New Biological Product Approvals for 2008 . . . . .	304
Summary of CBER Actions in 2008 . . . . .	305
Key CBER Review Statistics for 2008 . . . . .	305
CBER's New Biological Product Approvals for 2008 . . . . .	305
Summary of CBER Actions in 2007 . . . . .	306
Key CBER Review Statistics for 2007 . . . . .	306
CBER's New Biological Product Approvals for 2007 . . . . .	306
Summary of CBER Actions in 2006 . . . . .	307
Key CBER Review Statistics for 2006 . . . . .	307
CBER's New Biological Product Approvals for 2006 . . . . .	307

Summary of CBER Actions in 2005 . . . . .	308
Key CBER Review Statistics for 2005 . . . . .	308
CBER's New Biological Product Approvals for 2005 . . . . .	308
Summary of CBER Actions in 2004 . . . . .	309
Key CBER Review Statistics for 2004 . . . . .	309
CBER's New Biological Product Approvals for 2004 . . . . .	309
Summary of CBER Actions in 2003 . . . . .	310
Key CBER Review Statistics for 2003 . . . . .	310
CBER's New Biological Product Approvals for 2003 . . . . .	310
Summary of CBER Actions in 2002 . . . . .	311
Key CBER Review Statistics for 2002 . . . . .	311
CBER's New Biological Product Approvals for 2002 . . . . .	311
Summary of CBER Actions in 2001 . . . . .	312
Key CBER Review Statistics for 2001 . . . . .	312
CBER's New Biological Product Approvals for 2001 . . . . .	312
Summary of CBER Actions in 2000 . . . . .	313
Key CBER Review Statistics for 2000 . . . . .	313
CBER's New Biological Product Approvals for 2000 . . . . .	313
<i>Orphan Drugs</i>	
Orphan Drug Designation and Approval Statistics, 1990-2009 . . . . .	314
Cumulative Growth of Orphan Drugs, 1984-2009 . . . . .	314
Orphan Drug Approval Times vs. Approval Times of Other Drugs, 1993-2009 . . . . .	314
Orphan Drug and Biologic Approvals, 1993-2009 . . . . .	314
Orphan Drug and Biologic Approvals in 1990, 1991, and 1992. . . . .	316
<i>Over-the-Counter Drugs</i>	
Rate of Rx-to-OTC Switches per Year, 1951-2009 . . . . .	316
<i>Generic Drugs</i>	
Generic Drug Approval Times: Median Time to Approval 1993 to 2009 . . . . .	317
Pending ANDAs Continue to Surge at FDA, 2000-2009 . . . . .	317
Mean and Median ANDA/AADA Review Times, 1995-2009 . . . . .	317
Annual ANDA and AADA Submission and Approval Statistics, 1995-2009 . . . . .	317
<i>Compliance</i>	
CDER Clinical Site Inspection Results, FY1998-FY2009 . . . . .	318
CDER Clinical Investigator Inspections, FY1992-FY2009 . . . . .	318
Clinical Investigator Deficiency Categories, FY2009. . . . .	318
Clinical Investigator Inspections Final Classification, FY2009 . . . . .	318
Clinical Investigator Deficiencies-CDER, FY2009 Final Classification of OAI . . . . .	318

## **Section 5: International Statistics**

### *European Union*

R&D Spending in Europe's Pharmaceutical Industry, 1980-2009 . . . . .	319
Pharmaceutical R&D Spending Within EFPIA Countries, 1990-2008. . . . .	319
Mean EMA Review Time for Human Drugs Submitted Under the EC's Centralized Procedure, 2009 . . . . .	320
Mean EMA Processing Time for Human Medicinal Products, 1997-2009 . . . . .	320
Mean Processing Times for Key Stages of Centralized Process, 1996-2009 . . . . .	320
Cancer, Anti-Infective, Blood, and Cardiovascular Drugs Dominate New Centralized Submissions to EMA in 2009 . . . . .	320
New Drug Reviews at the FDA and EMA: A 2009 FDA Analysis . . . . .	321
Comparison of New Molecular Entity Outcomes for FDA and EMA . . . . .	321
Review Outcomes for New Molecular Entities Having Similar Submission Timing at Both FDA and EMA . . . . .	321
Review Outcomes for New Molecular Entities Having Similar Submission Timing at Both FDA and EMA:	
Priority and Standard Applications . . . . .	321
Europe Moves to Keep Biotech Sector Afloat . . . . .	322
Product Development Phase of Europe's SMEs . . . . .	322
UK Clinical Trial Standards Under Fire . . . . .	322
The Current State of Pharmaceutical Innovation in Europe: A 2008 Assessment . . . . .	323

Percentage of Products in Development Considered to Have a Novel Mode of Action, 2001 vs. 2006 . . . . .	323
Proportion of Total Global R&D by Therapeutic Area, 2004 vs. 2006 . . . . .	324
<i>United Kingdom</i>	
The MHRA’s Clinical Trials Work, 2008/2009 . . . . .	325
MHRA’s New Active Substances Assessed and Mean Assessment Times, 1993-2009 . . . . .	325
Roche and Novartis: Being in UK Not So “NICE”. . . . .	325
<i>Japan</i>	
Pharmaceutical R&D Expenditures in Japan, 1985-2008 (in bill. Yen) . . . . .	326
Annual Number of New Chemical Entities Approved in Japan, 1983-2008 . . . . .	326
Number of INDs for Investigational New Drugs Submitted in Japan, FY2002-2008 . . . . .	326
Success Rates of New Drug Development in Japan, 2004-2008 . . . . .	326
R&D Expenditures of 20 Leading Japanese Pharmaceutical Manufacturers, 2005-2008 . . . . .	327
Number of Prescription Drug Manufacture and Import Approvals Granted in Japan, 1985-2008. . . . .	327
Median NDA Approval Times in Japan by Year of Submission, 1996-2007. . . . .	327
Median Development Times for NMEs in Japan, 2000-2007. . . . .	327
Number of Drugs in Development in Japan by Pipeline Stage and Disease/Therapeutic Category, 2010 . . . . .	328
Are Japan and European Pharmas More Innovative Than U.S. Pharmas? . . . . .	329
China and Biotech . . . . .	329
<i>Canada</i>	
Canadian Drugs Directorate New Active Substance (NAS) Approval Times, 1996-2009. . . . .	329
R&D Spending by Canadian Drug (Rx&D Member) Companies, 1984-2008. . . . .	330
New Drug Submission (NDS) Approval Times in Canada, 1998-2009 . . . . .	330
<i>Germany</i>	
Pharmaceutical R&D Expenditures by German Drug Industry, 1999-2008 . . . . .	331
Number of New Chemical Entities Approved in Germany, 1988-2008 . . . . .	331
The VFA Assesses the German Pharmaceutical Environment . . . . .	331
<i>Latin America</i>	
Global Clinical Trials: A Focus on Latin America . . . . .	332
Number of Clinical Studies Conducted in Key Emerging Market Countries . . . . .	332
Growth in Clinical Trials for Selected Major and Emerging Countries and Regions, 1999 to 2009. . . . .	332
Country Participation in Clinical Trials Evolution During the Last Three Years. . . . .	333
Selected Countries/Regions Participating in Phase III Clinical Trials, 2008 vs. 2009 . . . . .	333
Growth in Clinical Trials in Selected Latin American Countries, 2005-2008 vs. 2009 . . . . .	333
<i>Global</i>	
Comparative R&D Spending, Sales, and Product Launch Trends Worldwide: A 2010 Analysis . . . . .	334
Breakdown of World Pharma Market—2009 Sales . . . . .	334
Markets of First Launch for 25 New Active Substances Introduced in 2009 . . . . .	334
Pharmaceutical R&D Expenditure Annual Growth Rate, US vs. Europe, 1994-2009 . . . . .	334
Pharmaceutical R&D Expenditure in Europe, the United States, and Japan, 1990-2009. . . . .	334
U.S., European, Canadian and Asia/Pacific Biotech: Global Activity Measures, 2009 . . . . .	335
UK Sees Continued Fall in Clinical Trial Activity . . . . .	335
Trends in Worldwide Pharma and Biotech R&D Expenditures, 2002-2016P . . . . .	336
Global R&D Spending by World’s Top 500 Pharma & Biotech Companies, 2002-2016 . . . . .	336
Trends in Worldwide R&D Expenditure, 1993-2008P . . . . .	337
Global New Active Substance Product Launches, 2009 . . . . .	337
China Ushers in a New Era of Innovation. . . . .	338
Number of Active Trials Sites (Recruiting or Ongoing) in China by Top Disease Areas . . . . .	338
SFDA Accredited Sites . . . . .	338
Outsourced Clinical Research Market Size in China . . . . .	339
“Alignment” with EMA Preferable, But Not Everything—Pazdur . . . . .	339
Central and Eastern Europe’s Participation in Global Clinical Trials: A 2008 Assessment . . . . .	340
Growth in Emerging Markets, 2002-2007. . . . .	340
CEE Investigators Increase Participation in Global Studies, 2003-2007 . . . . .	340
Proportion of Trials in Various CEE Countries, 2002-2007 . . . . .	341
India’s Proportion of Clinical Trials to Double, 2007-2012—RNCOS . . . . .	342
Russia Sets Sights on Russian Drug Market . . . . .	342

Pharma Outsourcing in Asia: A 2008 Assessment of Key Dimensions in Various Countries.....	343
Framework for evaluating outsourcing destinations .....	343
Outsourcing Index—ranking of Asian territories across all factors .....	343